SCHEMBL21494401

SCHEMBL21494401

C=CC(=O)Oc1c([N+](=O)[O-])cnc2ccc(Br)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.39
TSHR P16473 1/20 0.39
MAPT P10636 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPK1 P28482 2/20 0.36
TNF P01375 1/20 0.36
POLB P06746 1/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
NOD2 Q9HC29 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NOD1 Q9Y239 1/20 0.36
PTGES O14684 1/20 0.35
EGFR P00533 5/20 0.35
FYN P06241 2/20 0.34
SRC P12931 2/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21494448 0.84 HTT (0.46) HTTTSHRMAPTMEN1KMT2A
SCHEMBL21494374 0.83 HTT (0.45) HTTTSHRMAPTMEN1KMT2A
SCHEMBL21494361 0.80 HTT (0.38) HTTTSHRMAPTMEN1KMT2A
SCHEMBL21494375 0.80 HTT (0.40) HTTTSHRMAPTMEN1KMT2A
SCHEMBL28468025 0.76 EGFR (0.42) HTTTSHRMAPTMEN1KMT2A
SCHEMBL358629 0.75 MAPT (0.45) HTTTSHRMAPTMEN1KMT2A
SCHEMBL25296877 0.74 RAB9A (0.38) MAPTMEN1KMT2AALDH1A1MAPK1
SCHEMBL358123 0.72 EGFR (0.42) HTTTSHRMAPTMEN1KMT2A
SCHEMBL1557518 0.72 LMNA (0.41) HTTTSHRMAPTMEN1KMT2A
SCHEMBL20319134 0.72 CTSB (0.42) HTTTSHRMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3784671-A1 DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY XRad Therapeutics, Inc. (US) 2021-03-03 EP disclosed
WO-2019201283-A1 DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY XRAD THERAPEUTICS, INC. (US) 2019-10-24 WO disclosed